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Introduction
The work in this proposal is designed to investigate the role of pericentrin as an oncogene and centrosme-damage-checkpoint protein in prostate normal and cancer cells. Pericentrin is a centrosome protein involved in organizing mitotic spindles to ensure proper chromosome segregation ( I ) . The two poles of mitotic spindle during cell division are formed by a pair of centrosomes, each of which is composed of an amorphous matrix and two microtubule barrels called centrioles (2) . Each centriole duplicates once per cell cycle and requires 1.5 cell cycles to mature (3). Previous work from our laboratory and another group revealed that centrosome defects were present in nearly all prostate cancers (4) (5) (6) . In other work we showed that modulating pericentrin levels by over-expression or siRNA-mediated depletion can lead to a variety of centrosome defects, including centrosome amplification, spindle defects, the loss of centrioles/centrosomes and the loss of cilia (7, 8) . We later characterized a novel centrosome-damage-checkpoint (CDC) in normal human diploid cells, which can be activated upon pericentrin depletion (8) . The activation of this checkpoint also requires functional p53 and p38 and leads to GI arrest (8) . In cancer cells with defective regulatory pathways (p53 or p38), we found that the CDC activation induced cancer-cell-specific cell death, but we did not look at cell cycle arrest. Because this "poisoning" strategy is highly selective, we planned to explore its applicability to treat prostate tumors with an abrogated p53 pathway (e.g. PC3 and DU-145).
Body
Over the last year, I tested whether the CDC induced GI-arrest in normal prostate cells and in p53-functional cancer cells, but apoptotic death in p53-abrogated cancer cells. While cell death was observed it was not substantial even after long period of protein depletion. However, during the course of these studies, we noticed that all prostate cells treated with pericentrin siRNA were more likely to fail in cytokinesis at first and become polyploid and aneuploid later. These severe genomic changes are known to exacerbate the tumor progression and potentially drive tumorigenesis from benign to malignancy (9) .
It is possible that this mechanism of cell division failure could account for centrosome defects and amplification that we have consistently observed over the last several years in prostate tumors and tumor cell lines (5) (6) (7) . In fact, we believe that cytokinesis failure may be the primary mechanism by which centrosome defects and aneuploidy develop during prostate tumorigenesis. When a prostate cell fails cell division, it instantly becomes tetraploid (4N) with supernumerary centrosomes (twice the normal number).
31 the nextyear, I will explore the exciting possibilitythat pericentrin depletion leads to qtokinesis failwe. Taward thisgoal, I will examine the mechanism of-cytokinesis failure, identify pericentrin interacting proteins and understand how they function during cytokinesis. These studies will be another step toward the development of potential therapy for prostate cancer progression (centrosome defects are present as early as PIN lesions and in aggressive tumors. Cytokinesis is a therapeutic target that is rather novel and not a focus of most research groups or biotechnology companies.
Toward the goal of this proposal, we recently identified centriolin as a pericentrininteracting protein. Centriolin localizes to the midbody (10, I I), a complex protein structure composed of hundreds of proteins that is formed at the intercellular bridge that connects the two daughter cells late in cytokinesis (12) . The bridge needs to be resolved at the midbody by centriolin-involved asymmetric vesicle targeting (1 1, 12) as well as rearrangement of cytoskeletal elements andlor signaling proteins. Perhaps most exciting is the observation that CD133, a pan-stem cell marker, is highly enriched at midbodies (14) . The finding on midbodies described above suggest that these structures may have unexpected functions, some possibly unrelated to cytokinesis. Consistent with this idea, I
recently observed that midbody (MB) is accumulated in prostate cancer cells (Fi . 1); we P call these post-division midbodies midbody derivatives (MBds). In contrast, MB did not accumulate in normal prostate epithelial cells (gift of Dr. William C. Hahn, Harvard Medical School, Dana-Farber Cancer Institute). In addition, we showed that MBdcontaining cells were found in sections from human prostate tumors. Further studies demonstrated that MBd were found in a number of different cancer cell lines but rarely found in normal dividing, differentiating, or telomerase-immortalized cells (Fig. 1 ). MBds were also found in stem cells in many human and mouse tissues (e.g. the bulge of hair follicles, the spermatogonia layer of seminiferous tubules. Fig. 3 ) as well as human embryonic stem cells (hESCs, H 1 and H9) and mouse somatic cells induced to become stem cells (induced pluripotent stem cells. Fig. 2 ). Based on these surprising and provocative results, we propose that the ~B~-a c c u m u l a t i n~ cells may have stem cell qualities and may represent "prostate cancer stem cells" or "prostate cancer initiating cells". These results would be consistent with the stem cell theory of prostate cancer (15) .
Our previous results suggested that the inheritance and accumulation of MBds by one cell requires asymmetric MBd asymmetric vesicle targeting to the intercellular bridge (I I). To further test the mechanism of this asymmetric inheritance, I showed that the two daughter cells can be differentiated based one the age of the centrosome ages (Fig. 4) . Like DNA, the centrosome is replicated in a semi-conservative manner resulting in an old copy and a younger copy. Using GFP-tagged centrin 1, a centrosome protein able to discern centrosome ages and time-lapse imagin I found that the daughter cell with older PI centrosome preferentially received MB s (Fig. 5 ) and accumulated MBds in successive divisions.
We next asked where supernumerary MBds resided in the cell. The traditional view (fi-om the 1960-70s) is that they are either degraded extracellularly or jettisoned from the cell.
Hawever, these is not -we ohservd. Using wheat germ agglutinin to delineate plasma -. . . -mernbrane,~we~showed~that.~~~s~are~founded .beneath_the.cell.membranewithin_the cytoplasm (Fig. 6) . As far as I know, we are the first group to unequivocally show the intracellular localization of MBds.
We next examined the fate of MBds. Because they are rarely accumulated in normal cells, but regularly accumulated in prostate cancer cells (and other cancer cells), we reasoned that the degradation may play a role in the fate of these structures. To test this, we synchronized normal diploid cells (hRPE1) to facilitate synchronous generation of M B~S during mitosis. We found that -70% of M B~S were within lysosomes 3 hours after release from mitosis (Fig. 7) . With time, the number of M B~S in lysosomes decreased. In contrast, cancer cells' MBds did not appear to be delivered to lysosomes and thus appear to escape from or be delayed in degradation. Currently, we are testing whether inhibiting lysosomal enzyme activity would increase the number of MBdS in lysosomes in the normal cells. In addition, we are trying to understand mechanisms of M B~ degradation and how a subpopulation of prostate cancer cells accumulates MB~S. Also under investigation is the question of whether accumulated M B~S can affect cellular physiology, with an emphasis on their contribution to stem celllcancer "stem" cell biology 
Cell line (MCF7) express Centrin 1 -GFP were established to study how centriole age affects the MB inheritance.
Conclusion:
Progress during the last year includes three important progresses. Firstly, we found that post-mitotic M B~S are not disassembled extracellularly or actively jettisoned by the daughter cells. Instead, they appear to be degraded inside cells by lysosomes in normal diploid cells and remain free in the cytoplasm of prostate cancer cells. This entire pathway has been ignored for decades and we are the first group to systematically investigate this process. Secondly, we demonstrated that putative prostate cancer "stedinitiating cells" (and other cancer cells) accumulate M B~S in contrast to normal diploid cells that degrade them in lysosomes. This difference could be exploited to target prostate tumor cells versus normal prostate epithelial cells. Thirdly, we have established a link between M B~S inheritance and the age of centrioles. This finding could contribute to the mechanism of asymmetric vesicle delivery at the very end of cytokinesis, which appears to be a complex process with contributions from many pathways (12) . ..-MBds but mouse embryonic fibroblasts do not (see Fig. 1 ). 
